NASDAQ:SRPT

Sarepta Therapeutics Stock Forecast

etoro logo Buy SRPT
*Your capital is at risk
$17.18
+0.400 (+2.38%)
At Close: Aug 10, 2026

Should you buy SRPT stock?

Last updated:

Based on market data through , StockInvest.us rates Sarepta Therapeutics (SRPT) as a Buy Candidate with a technical score of 1.26 on its -10 to +10 scale. This is an upgrade from Sell in the previous daily evaluation.

  • Buy signal since
  • Price since signal Flat 0.00%
  • 3-month trend forecast Down 4.20%
  • Buy Candidate 1.26
AI Analysis AI Analysis of SRPT AI-Powered Market Insights
Stock Analysis PRO New!
Risk Assessment PRO New!
Trading Strategy PRO New!
Add SRPT to Watchlist?
Some Reasons Why To Add SRPT:
  • Lower volatility than the market (beta 0.20)
  • Highly efficient cash conversion (143% FCF/OCF ratio)
  • High gross margin of 58.6%
PDF

Stronger technical forecast for Sarepta Therapeutics stock price after Monday trading
(Market data through Aug 10, 2026)

SIGN UP FREE
or
Creating an account or logging in means you agree to StockInvest.us Terms of Use and Privacy Policy.
Buy candidate since Aug 10, 2026

The Sarepta Therapeutics stock price gained 2.38% on the last trading day (Monday, 10th Aug 2026), rising from $16.78 to $17.18. During the last trading day the stock fluctuated 5.07% from a day low at $16.38 to a day high of $17.21. The price has risen in 6 of the last 10 days and is up by 8.12% over the past 2 weeks. Volume fell on the last day by -759 thousand shares and in total, 2 million shares were bought and sold for approximately $39.01 million. You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days.

The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -4.20% during the next 3 months and, with a 90% probability hold a price between $13.82 and $19.36 at the end of this 3-month period.

SRPT Signals & Forecast

Mostly positive signals in the chart today. The Sarepta Therapeutics stock holds buy signals from both short and long-term Moving Averages giving a positive forecast for the stock, but the stock has a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections down, there will be some support from the lines at $16.26 and $17.17. A breakdown below any of these levels will issue sell signals. A buy signal was issued from a pivot bottom point on Friday, July 31, 2026, and so far it has risen 15.61%. Further rise is indicated until a new top pivot has been found. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell during the last trading day despite gaining prices. This causes a divergence between volume and price and it may be an early warning. The stock should be watched closely. The stock had a Golden Star Signal on Monday, June 29, 2026 in the short-term chart.

Golden Star Signal is when the short-term moving average, the long-term moving average, and price line meet in a special combination. This combination is very rare and often followed by long and strong gains for the stock in question.

Buy
Special Signal Notification

Golden Star

The stock had a Golden Star Signal on Monday, June 29, 2026 in the short-term chart.

Golden Star Signal is when the short-term moving average, the long-term moving average, and price line meet in a special combination. This combination is very rare and often followed by long and strong gains for the stock in question.

Support, Risk & Stop-loss for Sarepta Therapeutics stock

Sarepta Therapeutics finds support from accumulated volume at $16.85 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved $0.83 between high and low, or 5.07%. For the last week, the stock has had daily average volatility of 5.22%.

Our recommended stop-loss: $16.61 (-3.32%) (This stock has medium daily movements and this gives medium risk. There is a buy signal from a pivot bottom found 6 days ago.)

Trading Expectations (SRPT) For The Upcoming Trading Day Of Tuesday 11th

For the upcoming trading day on Tuesday, 11th we expect Sarepta Therapeutics to open at $16.92, and during the day (based on 14 day Average True Range), to move between $16.73 and $17.63, which gives a possible trading interval of +/-$0.90 (+/-5.38%) up or down from last closing price. If Sarepta Therapeutics takes out the full calculated possible swing range there will be an estimated 5.38% move between the lowest and the highest trading price during the day.

Since the stock is closer to the support from accumulated volume at $16.85 (1.92%) than the resistance at $17.53 (2.04%), our systems sees the trading risk/reward intra-day as attractive and believe profit can be made before the stock reaches first resistance..

Is Sarepta Therapeutics stock A Buy?

Several short-term signals are positive, despite the stock being in a falling trend, we conclude that the current level may hold a buying opportunity as there is a fair chance for stock to perform well in the short-term. We have upgraded our analysis conclusion for this stock since the last evaluation from a Sell to a Buy candidate.

Current score: 1.264 Buy Candidate Upgraded

Predicted Fair Opening Price

Predicted fair opening price on August 11, 2026 - $16.92 ( 1.49%).

Want to trade but not sure how? Our step-by-step guide can help.
Skip the guide? Open account with our trusted broker* eToro
*Your capital is at risk

SRPT Performance

Trading levels for SRPT

StockInvest.us
Full Access. No Commitment. Up to 14 Days Free!
Long & Short-Term Golden Star Lists
AI Stock Analysis*
Top 10 Candidates on Every List
Premium Lists
Ad-FREE Browsing
Advanced Stock Screener

Fibonacci Support & Resistance Levels

Level Price
R3 17.75 3.34%
R2 17.44 1.49%
R1 17.24 0.352%
Price 17.18
S1 16.61 -3.34%
S2 16.41 -4.48%
S3 16.09 -6.33%

Accumulated Volume Support & Resistance Levels

Level Price
R3 17.61 2.50%
R2 17.55 2.15%
R1 17.53 2.04%
Price 17.18
S1 16.85 -1.92%
S2 16.78 -2.33%
S3 15.88 -7.57%

FAQ

What is the symbol for Sarepta Therapeutics Stock and on which exchange is it traded?
The symbol for Sarepta Therapeutics is SRPT and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell Sarepta Therapeutics Stock?
Based on market data through Aug 10, 2026, StockInvest.us rates Sarepta Therapeutics (SRPT) as a Buy Candidate with a technical score of 1.26 on its -10 to +10 scale. This is an upgrade from Sell in the previous daily evaluation. Since the Buy signal began on Aug 10, 2026, the price has remained flat. The current 3-month trend forecast projects a fall of 4.20%.

How to buy Sarepta Therapeutics Stock?
Sarepta Therapeutics Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Sarepta Therapeutics Stock.

What's the current price of Sarepta Therapeutics Stock?
As of the end of day on the Aug 10, 2026, the price of an Sarepta Therapeutics (SRPT) share was $17.18.

What is the 52-week high and low for Sarepta Therapeutics Stock?
The 52-week high for Sarepta Therapeutics Stock is $25.32 and the 52-week low is $14.68.

What is the market capitalization of Sarepta Therapeutics Stock?
As of the Aug 10, 2026, the market capitalization of Sarepta Therapeutics is 1.814B.

When is the next earnings date for Sarepta Therapeutics?
The upcoming earnings date for Sarepta Therapeutics is Nov 04, 2026.
Click to get the best stock tips daily for free!
ABOUT SAREPTA THERAPEUTICS
Sarepta Therapeutics
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of ...
GOLDEN STAR
Ticker Change Signal Date
GPOR
$158.45
6.03% Aug 06
FCX
$62.63
12.61% Jul 31
BIIB
$202.19
2.44% Jul 24
TSCO
$30.32
14.18% Jul 23
S
SW
$43.71
8.88% Jul 23

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE